• Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV

    Gastroenterology Volume: 154 Issue: 4 Page: 989-997 Published: Mar 2018 IF= 18.392 ; 1.27% 5-year IF= 16.825

  • Management of patients on antithrombotic agents undergoing emergency and elective...

    Gut Volume: 67 Issue: 3 Page: 405-417 Published: Mar 2018 IF= 16.658 ; 2.53% 5-year IF= 14.759

  • PINK1 Phosphorylates MIC60/Mitofilin to Control Structural Plasticity of Mitochondrial Crista Junctions

    Molecular Cell Volume: 69 Issue: 5 Page: p744–756.e6 Published: 1 Mar 2018 IF= 14.714 ; 2.06% 5-year IF= 14.37

  • Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma

    Hepatology Volume: 67 Issue: 3 Page: 1132-1149 Published: Mar 2018 IF= 13.246 ; 5.06% 5-year IF= 11.93

  • 蚜蟲胚胎免疫染色技術重大突破—臺大昆蟲學系遺傳發育團隊研究成果榮登新型態學術期刊Journal of Visualized Experiments (JoVE)

  • 臺大昆蟲學系張俊哲教授和慈濟大學林明德教授共同合作AID計畫,解開昆蟲生殖蛋白Vasa重要演化發育意涵,可抑制生殖細胞形成遏止害蟲繁衍

  • The Taiwan Heart Registries Its Influence on Cardiovascular Patient Care

    Journal of The American College of Cardiology Volume: 71 Issue: 11 Page: 1273-1283 Published: 20 Mar 2018 IF= 19.896 ; 1.59% 5-year IF= 18.456

  • Producing irreversible topoisomerase II-mediated DNA breaks by site-specific Pt(II)-methionine coordination chemistry

    Nucleic Acids Research Volume: 45 Issue: 18 Page: 10861-10871 Published: Oct 13 2017 IF= 10.162 ; 4.81% 5-year IF= 9.338

  • LANCET Volume: 391 Issue: 10123 Page: 839-849 Published: 3 Mar 2018 IF= 47.831 ; 1.28% 5-year IF= 48.082

    Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

  • Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

    LANCET Volume: 391 Issue: 10126 Page: 1163-1173 Published: 24 Mar 2018 IF= 47.831 ; 1.28% 5-year IF= 48.082

Browse by